Matoke® Holdings Ltd is developing its patented Reactive Oxygen® technology as novel treatments which are much more than conventional antibiotics.
Reactive Oxygen® technology is a novel antimicrobial platform creating treatments for chronic and acute indications with potential for accelerated wound healing, biofilm penetration, tissue regeneration, immune system stimulation and potential efficacy against Gram-positive and Gram-negative pathogenic bacteria, as well as pathogenic fungi and viruses.
With the World Health Organisation predicting that millions may die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology offers a potential solution to the global AMR threat which can help save lives.
0
People per yeardie from AMR
worldwide
0 million
by 2025could die annually
without action
£0
Millionannual cost of AMR
to the NHS
Matoke Holdings on Twitter
Understanding how biofilms are formed is paramount to understanding how to defeat them. #StopSuperbugs
Chipping Away At The Problem Of Biofilms
Scientists in Japan have invented a tool that could be used to better understand biofilm kinetics.
www.asianscientist.com
It's time #StopSuperbugs now. Matoke are working on #ReactiveOxygen to help mitigate the challenge.
Before the discovery of antimicrobials, 43% of people died from infections. Without effective antimicrobials @CMO_England warns that modern medicine will be lost. @CommonsHealth continues its inquiry into the serious problem of rising #AntimicrobialResistance 2.30pm today
A new paper by the LSE's @MOSSIALOS and @mattjrenwick highlights the economic barriers to antibiotic R&D. It's more important than ever that governments provide more funding to overcome the #AMR challenge #StopSuperbugs
Sign up to the newsletter